Filgrastim biosimilar - Mycenax Biotech

Drug Profile

Filgrastim biosimilar - Mycenax Biotech

Alternative Names: GranNEX

Latest Information Update: 04 Aug 2015

Price : $50

At a glance

  • Originator Mycenax Biotech
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
  • Mechanism of Action Granulocyte colony stimulating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Neutropenia

Highest Development Phases

  • Preregistration Neutropenia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 04 Jun 2015 Filgrastim biosimilar - Mycenax Biotech is available for licensing in World as of 04 Jun 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top